Dublin, Sept. 14, 2017 -- The "Plasmapheresis Market - Global Opportunity Analysis and Industry Forecasts to 2022" report has been added to Research and Markets' offering.
Global plasmapheresis market is expected to reach USD 1,285.3 million by 2022 supported by a CAGR of 8.3% during the forecast period of 2017 to 2022.
The growth in this market is majorly driven by increasing incidence & prevalence of various autoimmune disorders, rising demand for source plasma from biopharmaceutical companies, and favorable reimbursement policies for plasmapheresis procedures. However, high cost of plasmapheresis procedure and lack of awareness about plasmapheresis will hamper the growth of this market to some extent during the forecast period.
Key questions answered in the report:
- Which are the high growth market segments in terms of product type, technology, application, end user and regions/countries?
- What is the historical market for plasmapheresis across the globe?
- What are the market forecasts and estimates from the period 2015-2022?
- What are the major drivers, restraints, opportunities and trends in the global plasmapheresis market?
- Who are the major players in various countries and what share of the market do they hold?
- What are the recent developments in the global plasmapheresis market?
- What are the different strategies adopted by the major players in the global plasmapheresis market?
- What are the geographical trends and high growth regions/ countries?
- Who are the local emerging players in the global plasmapheresis market and how do they compete with the global players?
Key Topics Covered:
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Increasing Incidence of Autoimmune Diseases
4.2.1.2. Increasing Demand for Source Plasma from Biopharmaceutical Companies
4.2.1.3. Favorable Reimbursement Policies for Plasmapheresis Procedures
4.2.2. Restraints
4.2.2.1. High Cost of Plasmapheresis Devices & Procedures
4.2.2.2. Lack of Awareness About Plasmapheresis Procedures
4.2.2.3. Risk Associated with Plasmapheresis Procedures
4.2.3. Opportunity
4.2.3.1. Rising Demand for Plasmapheresis from Emerging Countries
4.3. Market Share Analysis, by Key Players
5. Plasmapheresis Market, By Product Type
5.1. Introduction
5.2. Instruments
5.3. Disposables
6. Plasmapheresis Market, By Technology
6.1. Introduction
6.2. Membrane Filtration
6.3. Centrifugation
7. Plasmapheresis Market, By Application
7.1. Introduction
7.2. Therapeutic Plasmapheresis
7.3. Source Plasma Collection
8. Plasmapheresis Market, By End User
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Hospitals & Clinics
8.4. Others
9. Geographic Analysis
9.1. Introduction
9.2. North America
9.3. Europe
9.4. Asia-Pacific
9.5. Rest of The World
10. Company Profiles
10.1. Asahi Kasei Corporation
10.2. Terumo Corporation
10.3. Baxter International Inc.
10.4. B. Braun Melsungen Ag
10.5. Kawasumi Laboratories Inc.
10.6. Kaneka Corporation
10.7. Haemonetics Corporation
10.8. Fresenius Se & Co. Kgaa
10.9. Shanghai Dahua Medical Apparatus Co., Ltd.
10.10. Infomed Sa
11. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/cw2gz5/plasmapheresis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Blood Banking


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



